Morgan Stanley Forecasts Strong Price Appreciation for CG Oncology (NASDAQ:CGON) Stock

CG Oncology (NASDAQ:CGON – Get Free Report) had its target price boosted by equities researchers at Morgan Stanley from $102.00 to $117.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley‘s price target indicates a potential upside of 42.86% from the stock’s previous close.

Several other research firms have also recently weighed in on CGON. Piper Sandler increased their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Guggenheim dropped their target price on shares of CG Oncology from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Monday, November 9th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Truist Financial reaffirmed a “buy” rating and set a $100.00 price target (up from $85.00) on shares of CG Oncology in a research report on Tuesday. Finally, Wall Street Zen upgraded CG Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $102.22.

Check Out Our Latest Stock Report on CGON

CG Oncology Stock Performance

NASDAQ:CGON opened at $81.90 on Wednesday. The company has a market capitalization of $7.32 billion, a PE ratio of -29.67 and a beta of 0.35. The company has a 50 day simple moving average of $68.71 and a two-hundred day simple moving average of $67.10. CG Oncology has a fifty-two week low of $37.01 and a fifty-two week high of $93.95.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. Research analysts predict that CG Oncology will post -2.97 EPS for the current year.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $92.00, for a total transaction of $92,000.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at $92,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Isabel Kalofonos bought 3,751 shares of CG Oncology stock in a transaction dated Wednesday, November 18th. The stock was purchased at an average price of $79.75 per share, with a total value of $299,142.25. Following the completion of the purchase, the insider owned 3,751 shares in the company, valued at $299,142.25. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 3,000 shares of company stock valued at $227,040 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds have recently added to or reduced their stakes in CGON. BlackRock Inc. bought a new stake in shares of CG Oncology during the second quarter valued at approximately $444,509,000. Seven Fleet Capital Management LP raised its position in shares of CG Oncology by 24.5% during the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after purchasing an additional 371,085 shares during the period. Bank of America Corp DE raised its position in shares of CG Oncology by 21.8% during the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock worth $98,093,000 after purchasing an additional 259,311 shares during the period. Goldman Sachs Group Inc. raised its position in shares of CG Oncology by 32.5% during the third quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after purchasing an additional 278,751 shares during the period. Finally, EcoR1 Capital LLC lifted its holdings in shares of CG Oncology by 3.5% in the 1st quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock worth $74,583,000 after purchasing an additional 37,200 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

Trending Headlines about CG Oncology

Here are a few of the latest headlines about CGON:

  • Positive Sentiment: Guggenheim raised its price target to $120 and maintained a Buy rating. Morgan Stanley also lifted its target to $117 and reiterated Overweight, adding to favorable analyst sentiment. Guggenheim analyst rating
  • Positive Sentiment: HC Wainwright kept its Buy rating and $115 target while raising its EPS forecasts for FY2028, FY2029 and FY2030. The higher estimates suggest the analyst sees improving longer-term earnings potential. HC Wainwright analyst outlook
  • Negative Sentiment: Director Leonard Post sold 1,000 shares, halving his direct stake. The sale was relatively small compared with the company’s overall value, and was outweighed in scale by the reported insider purchases. Director’s SEC filing

About CG Oncology

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Further Reading

Analyst Recommendations for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.